43.46
-1.47(-3.27%)
Currency In USD
| Previous Close | 44.93 |
| Open | 44.85 |
| Day High | 45.44 |
| Day Low | 43.33 |
| 52-Week High | 58.4 |
| 52-Week Low | 21.34 |
| Volume | 1.28M |
| Average Volume | 1.17M |
| Market Cap | 3.48B |
| PE | -11.41 |
| EPS | -3.81 |
| Moving Average 50 Days | 49.09 |
| Moving Average 200 Days | 43.39 |
| Change | -1.47 |
If you invested $1000 in Akero Therapeutics, Inc. (AKRO) since IPO date, it would be worth $2,372.27 as of September 12, 2025 at a share price of $43.46. Whereas If you bought $1000 worth of Akero Therapeutics, Inc. (AKRO) shares 5 years ago, it would be worth $1,182.59 as of September 12, 2025 at a share price of $43.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Aug 28, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need,
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
GlobeNewswire Inc.
Aug 14, 2025 10:30 PM GMT
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASHSOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-sta
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 03, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need,